Biologics Used for Psoriasis: A Drug Utilization Study Based on Two Nationwide Danish Data Sources
Pharmacoepidemiology and Drug Safety · 2024
DOI: 10.1002/pds.70050 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Nanna Philbert Engel-Andreasen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark. Hauptthemen laut MEDLINE: Psoriasis, Biological Products, Registries, Drug Utilization. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: University of Southern Denmark, Syddansk Universitet.
Abstract (Originalsprache)
Purpose
Biological treatment has been a game changer in the management of moderate‐to‐severe psoriasis. In Denmark, biological treatment for psoriasis is registered in two data sources. We aimed to describe the utilization of biologics for psoriasis in Denmark using data from both data sources separately.
Methods
We used data from two different nationwide Danish data sources: The healthcare registries and the clinical quality database, Dermbio. Utilization patterns were described by three different parameters: (1) distribution of drugs used in the first treatment episodes, (2) treatment cascade on a population level, and (3) drug survival using Kaplan Meier (KM) analysis and the proportion of patients covered (PPC) method.
Results
From January 1, 2011, to December 31, 2018, we found 1878 users of biologics in the healthcare registries and 2264 in Dermbio. Adalimumab, ustekinumab, and secukinumab were the most common first‐choice treatments throughout the study period. According to the healthcare registries, it was most common to have more than one treatment episode with the same drug. In Dermbio, most were registered to have only one observable treatment episode overall in the study period. Ustekinumab showed the longest drug survival in both databases. Drug survival was longer for all biologics in Dermbio than in the healthcare registries.
Conclusion
Adalimumab, ustekinumab, and secukinumab were the most common first‐choice treatments in Denmark. Overall, ustekinumab showed the longest drug survival. We observed important differences in treatment cascades and drug survival between Dermbio and the healthcare registries, which should be considered when using these data sources to perform drug utilization studies on biologics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark.
- Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Nanna Philbert Engel-Andreasen, Jesper Hallas
Förderung
- University of Southern Denmark
- Syddansk Universitet
Zitieren
APA
Engel-Andreasen, N. P., Hallas, J., Jensen, P., Egeberg, A., & Reilev, M. (2024). Biologics Used for Psoriasis: A Drug Utilization Study Based on Two Nationwide Danish Data Sources. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70050
Vancouver
Engel-Andreasen NP, Hallas J, Jensen P, Egeberg A, Reilev M. Biologics Used for Psoriasis: A Drug Utilization Study Based on Two Nationwide Danish Data Sources. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.70050
BibTeX
@article{EngelAndreasen2024,
author = {Engel-Andreasen, Nanna Philbert and Hallas, Jesper and Jensen, Peter and Egeberg, Alexander and Reilev, Mette},
title = {Biologics Used for Psoriasis: A Drug Utilization Study Based on Two Nationwide Danish Data Sources},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2024},
doi = {10.1002/pds.70050}
}
EUVIMED